Safety and Efficacy of Consolidation Therapy with Ipilimumab Plus Nivolumab after Autologous Stem Cell TransplantationAlan P Skarbnik, Andrew L. Pecora, Pashna N. Munshi et al.|Transplantation and Cellular Therapy|2020Cited by 16
Phase Ib-II Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib, w/ Lenalidomide and Rituximab in Relapsed / Refractory Mantle Cell LymphomaAndré Goy, Ernest Richards, Tatyana Feldman et al.|Blood|2017Cited by 1
Influence of the Gut Microbiome on Clinical Outcomes in the CPIT-001 Trial, a Phase Ib-IIA Study of Combined Checkpoint Inhibition with Nivolumab and Ipilimumab after Autologous Hematopoietic Stem Cell Transplantation in Patients at High-Risk for Post-Transplant RecurrenceRena Feinman, Andrew L. Pecora, Tracy Andrews et al.|Blood|2018Cited by 0